Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly providing misleading statements about its business growth and performance during the class period from May 2, 2024, to May 6, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Vestis securities during the specified class period [1]. - Investors have until August 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Vestis - The complaint alleges that Vestis made overwhelmingly positive statements while concealing material adverse facts about its business growth capabilities [3]. - Specifically, it is claimed that Vestis would be unable to execute planned strategic initiatives aimed at improving customer experience and driving new customer growth [3]. Group 3: Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year [4]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [4]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of their potential entitlement to compensation through a class action lawsuit [1][4]. Group 1: Class Action Details - The Class Period for the RxSight securities is from November 7, 2024, to July 8, 2025, and the lead plaintiff deadline is September 22, 2025 [1][2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. Group 2: Allegations Against RxSight - The lawsuit alleges that RxSight made false and misleading statements regarding its business performance, including issues with product adoption and overstated demand [4]. - It is claimed that RxSight was unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. - The misleading statements led to investor damages when the true situation was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible for compensation through a class action lawsuit [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Petco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 30, 2025 (GLOBE NEWSWIR ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, of the upcoming lead plaintiff deadline on August 29, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Petco securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-related business model and the strength of its product strategy [5]. - It is claimed that the defendants downplayed the severity of issues affecting Petco's business and overstated its ability to achieve sustainable, profitable growth [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading public statements made by the defendants [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between November 7, 2024, and July 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against RxSight, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false and misleading statements regarding the company's sales and product demand [4]. - Specific issues cited include "adoption challenges" leading to declines in sales and utilization, overstated demand for products, and an inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, due to significant declines in sales and lowered revenue guidance [5].

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false and misleading statements regarding its business performance and financial guidance during the Class Period from November 7, 2024, to July 8, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [5]. - Defendants allegedly overstated the demand for RxSight's products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [5]. - The misleading statements made by the defendants about RxSight's business operations and prospects caused investors to suffer damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased RxSight securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by September 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Flywire Corporation, alleging misrepresentations regarding the company's revenue growth between February 28, 2024, and February 25, 2025 [1][2]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Flywire's securities during the specified period [1]. - Defendants are accused of making false statements about the strength and sustainability of Flywire's revenue growth [2]. Lead Plaintiff Information - Interested parties must file papers by September 23, 2025, to serve as lead plaintiff, representing the class in the litigation [3]. - Participation as a lead plaintiff is not required to share in any potential recovery, and shareholders incur no fees or expenses [3]. Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions [4].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who purchased the securities of Flywire Corporation ("Flywire" or the "Company") (NASDAQ: FLYW) between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"). According to the Complaint, following the foregoing disclosures and analyst down ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. following a significant drop in stock price after the FDA issued a Complete Response Letter regarding its Biologics License Application for RP1 [3][6][7] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal options [1] - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [3][8] - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4] Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives violated federal securities laws by making false or misleading statements regarding the IGNYTE trial's prospects [5] - It is claimed that the defendants overstated the trial's prospects, leading to the FDA deeming it inadequate and not well-controlled [5][6] - Following the FDA's announcement, Replimune's stock plummeted over 73% during intraday trading on July 22, 2025 [7] Group 3: Company Communication - On July 22, 2025, Replimune announced it received a Complete Response Letter from the FDA, indicating that the application could not be approved in its current form [6] - The FDA's response highlighted that the IGNYTE trial did not provide substantial evidence of effectiveness [6]